Home › Funds › Bellevue Group AG › VRTX

Bellevue Group AG position in VRTX

VERTEX PHARMACEUTICALS INC · Health Care

Bellevue Group AG reported holding 578,634 shares of VRTX (VERTEX PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$287.4M, representing 6.05% of its reported portfolio and ranking #2 among its reported holdings. Bellevue Group AG has disclosed VRTX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)578.63K sh
Reported value held$287.42M
Portfolio Weight6.05%
First reportedQ3 2023
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Bellevue Group AG's VRTX position evolved

Bellevue Group AG first disclosed a stake in VRTX in Q3 2023 at 1,002,735 shares (US$348.7M). Across 12 filings, Bellevue Group AG increased the stake 3 time(s), trimmed it 7 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 578,634 shares valued at US$287.4M — a reduction of -103,274 shares quarter over quarter.. Notable position changes include a 27% trim in Q4 2023 (shares rose 2% over the following quarter), a 35% increase in Q4 2025 (shares fell 1% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 1.00M $348.69M New
Q4 2023 736.39K $299.63M Reduce
Q1 2024 668.75K $279.54M Reduce
Q2 2024 593.46K $278.17M Reduce
Q3 2024 571.41K $265.75M Reduce
Q4 2024 487.43K $196.29M Reduce
Q1 2025 413.07K $200.27M Reduce
Q2 2025 441.61K $196.60M Add
Q3 2025 505.81K $198.09M Add
Q4 2025 681.12K $308.79M Add
Q1 2026 681.91K $304.50M Hold
Q2 2026 578.63K $287.42M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About VRTX and 13F data

VRTX (VERTEX PHARMACEUTICALS INC) is a Health Care company. 33 other funds we track also report a position in VRTX — the largest reported positions include Capital World Investors (US$12.97B), Capital World Investors (US$12.97B), Capital Research Global Investors (US$9.68B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding VRTX

All VRTX fund holders →

FAQ

How long has Bellevue Group AG held VRTX?

Bellevue Group AG has disclosed VRTX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is Bellevue Group AG's current position in VRTX?

As of Q2 2026, Bellevue Group AG holds 578.63K shares of VRTX (VERTEX PHARMACEUTICALS INC), valued at $287.42M, representing 6.05% of its reported portfolio and ranking #2.

Has Bellevue Group AG been buying or selling VRTX?

In the latest 13F filing (Q2 2026), Bellevue Group AG reduced its position in VRTX.

Which other funds hold VRTX?

Other major institutional holders of VRTX include Capital World Investors, Capital World Investors, Capital Research Global Investors, among 33 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.